Clinical Trials

60 enrolled

Urinary Bladder Neoplasms

NCT03866382 2026-03-18

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

314 enrolled

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT04981509 2026-03-18

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

65 enrolled

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

NCT05691465 2026-03-18

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Prostatic Neoplasms

NCT06022822 2026-03-18

Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

90 enrolled

Prostate Adenocarcinoma

NCT06770582 2026-03-18

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

160 enrolled

Urinary Bladder Neoplasms

NCT07061964 2026-03-18

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

111 enrolled

Urinary Bladder Neoplasms

NCT06161532 2026-03-17

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

60 enrolled

Carcinoma, Transitional Cell

NCT07111507 2026-03-17

A Study of Tarlatamab for People With Prostate Cancer

32 enrolled

Prostatic Neoplasms

NCT07332000 2026-03-17

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

45 enrolled

Adenocarcinoma, Prostatic Neoplasms

NCT07476001 2026-03-17

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

12 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT03547973 2026-03-16

TROPHY U-01

827 enrolled 1 FDA

Metastatic Urothelial Cancer

NCT05751941 2026-03-16

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

26 enrolled

Prostatic Neoplasms

NCT06096870 2026-03-16

Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy

65 enrolled

Prostatic Neoplasms

NCT06863311 2026-03-16

EXACT

70 enrolled

Carcinoma, Renal Cell

NCT06995677 2026-03-16

SURF302

90 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT05616650 2026-03-13

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

42 enrolled

Prostatic Neoplasms

NCT06173362 2026-03-13

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

75 enrolled

Prostatic Neoplasms

NCT06288113 2026-03-13

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

40 enrolled

Prostatic Neoplasms

NCT06654336 2026-03-13

RATIONAL

162 enrolled

Prostate Adenocarcinoma

NCT06708949 2026-03-13

A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)

15 enrolled

Carcinoma, Renal Cell

NCT07025369 2026-03-13

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

Prostatic Neoplasms

NCT07335796 2026-03-13

A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer

Prostatic Neoplasms

NCT07469683 2026-03-13

An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma

78 enrolled

Carcinoma, Renal Cell, Neoplasms

NCT05361798 2026-03-12

T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy

65 enrolled

Prostatic Neoplasms

NCT07050771 2026-03-12

Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery

148 enrolled

GenitourinaryGynecologic

Urinary Bladder Neoplasms, Kidney Neoplasms, Neoplasms, Ovarian Neoplasms

NCT06437574 2026-03-11

Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer

140 enrolled

Prostatic Neoplasms

NCT06488222 2026-03-11

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

34 enrolled

Urinary Bladder Neoplasms

NCT06216249 2026-03-10

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

90 enrolled

Prostatic Neoplasms

NCT06330805 2026-03-09

Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer

70 enrolled

Prostatic Neoplasms

NCT06957691 2026-03-09

Fezo-ADT

60 enrolled

EndocrineGenitourinary

Adenocarcinoma, Prostatic Neoplasms, Multiple Endocrine Neoplasia Type 1, Hot Flashes

NCT06528990 2026-03-05

Telehealth Intervention for Ostomy Self-Management

GastrointestinalGenitourinary

150 enrolled

Urinary Bladder Neoplasms, Colorectal Neoplasms

NCT07287150 2026-03-05

InavoPC

100 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT07451795 2026-03-05

SHARP

66 enrolled

Prostatic Neoplasms

NCT03609216 2026-03-04

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

271 enrolled

Infiltrating Bladder Urothelial Carcinoma

NCT06632977 2026-03-04

PREDICT

474 enrolled

Prostatic Neoplasms

NCT06675357 2026-03-04

Using FAPI PET/MRI to Evaluate Prostate Cancer

Prostatic Neoplasms

NCT06699602 2026-03-04

A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma

10 enrolled

Carcinoma, Renal Cell

NCT06760819 2026-03-04

panSOHO

BreastGastrointestinalGenitourinaryGynecologicSarcoma

111 enrolled

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors

NCT07005154 2026-03-03

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

218 enrolled

Prostatic Neoplasms

NCT07072728 2026-03-03

Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder